VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

TCT 2021 | First-line axicabtagene ciloleucel in lymphoma

Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of axicabtagene ciloleucel in the front-line setting for patients with relapsed/refractory non-Hodgkin lymphoma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter